| ID Source | ID |
|---|---|
| PubMed CID | 2802894 |
| CHEMBL ID | 333081 |
| CHEBI ID | 92436 |
| SCHEMBL ID | 8846980 |
| MeSH ID | M0201553 |
| Synonym |
|---|
| HMS3268A17 |
| ly288513 |
| ly 288513 |
| IDI1_031264 |
| ly262691 |
| MAYBRIDGE4_000682 |
| SR-01000630775-1 |
| NCGC00177312-01 |
| HMS1522O22 |
| (4s,5r)-3-oxo-4,5-diphenyl-pyrazolidine-1-carboxylic acid (4-bromo-phenyl)-amide |
| 3-oxo-4,5-diphenyl-pyrazolidine-1-carboxylic acid (4-bromo-phenyl)-amide(ly288513) |
| bdbm50092155 |
| (4s,5r)-n-(4-bromophenyl)-3-oxo-4,5-diphenylpyrazolidine-1-carboxamide |
| CHEMBL333081 , |
| ly-288513 |
| CCG-40648 |
| (4s,5r)-n-(4-bromophenyl)-3-oxo-4,5-diphenyl-1-pyrazolidinecarboxamide |
| BRD-K24675965-001-01-7 |
| gtpl3509 |
| 1-pyrazolidinecarboxamide, n-(4-bromophenyl)-3-oxo-4,5-diphenyl-, (4s,5r)- |
| 470GWP2CA0 , |
| 147523-65-7 |
| unii-470gwp2ca0 |
| SCHEMBL8846980 |
| AKOS024456648 |
| CHEBI:92436 |
| HMS3676H13 |
| Q27082731 |
| HMS3412H13 |
| BRD-K24675965-001-02-5 |
| BRD-K24675965-001-03-3 |
| HY-103357 |
| CS-0027722 |
| Class | Description |
|---|---|
| stilbenoid | Any olefinic compound characterised by a 1,2-diphenylethylene backbone. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cholecystokinin receptor type A | Rattus norvegicus (Norway rat) | IC50 (µMol) | 20.5000 | 0.0000 | 0.4362 | 4.3000 | AID53029 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID51118 | Half maximal inhibition of specific binding of [125I]Bolton-Hunter CCK-8 to Cholecystokinin type B receptor in the mouse cerebral cortex | 2000 | Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19 | Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists. |
| AID53029 | Half maximal inhibition of specific binding of [125I]-Bolton-Hunter CCK-8 to Cholecystokinin type A receptor in the rat pancreas | 2000 | Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19 | Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists. |
| AID234648 | Selectivity ratio of IC50 of CCK1 to that of CCK2 | 2000 | Journal of medicinal chemistry, Sep-21, Volume: 43, Issue:19 | Development of peptide 3D structure mimetics: rational design of novel peptoid cholecystokinin receptor antagonists. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| AID1346921 | Rat CCK2 receptor (Cholecystokinin receptors) | 2011 | Nature, Jan-13, Volume: 469, Issue:7329 | Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||